Elite in Bladder Cancer

Dr. Charles J. Rosser

Urology
888 South King Street, 
Honolulu, HI 
Clinical Trials:Currently Recruiting for 3 Trials
Elite in Bladder Cancer
888 South King Street, 
Honolulu, HI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Charles Rosser is an Urologist in Honolulu, Hawaii. Dr. Rosser is rated as an Elite provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 121 peer reviewed articles and participating in 12 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 85 articles and participated in 8 clinical trials in the study of Bladder Cancer.

Specialties
Urology
Licenses
Urology in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

888 South King Street, Honolulu, HI 96813
Other Locations
8700 Beverly Blvd, West Hollywood, CA 90048

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
A Study of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With Non-Muscle Invasive Bladder Cancer
Enrollment Status: Recruiting
Publish Date: October 14, 2025
Intervention Type: Biological
Study Drugs: Bacillus of Calmette-Guerin, ALT-803
Study Phase: Phase 1/Phase 2
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
Enrollment Status: Recruiting
Publish Date: October 06, 2025
A Novel Multiplex ELISA Assay for Surveilling Patients with History of Bladder Cancer
A Novel Multiplex ELISA Assay for Surveilling Patients with History of Bladder Cancer
Enrollment Status: Recruiting
Publish Date: February 19, 2025
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drugs: ALT-803, Bacillus Calumette-Guerin
Study Phase: Phase 2/Phase 3
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: October 09, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 03, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Gemcitabine Hydrochloride, Pembrolizumab
Study Phase: Phase 2
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Enrollment Status: Completed
Publish Date: May 22, 2025
Intervention Type: Drug
Study Drug: Atezolizumab
Study Phase: Phase 2
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)
Enrollment Status: Completed
Publish Date: January 13, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cabozantinib S-Malate, Crizotinib, Savolitinib, Sunitinib Malate
Study Phase: Phase 2
Radiogenomics of Muscle Invasive Bladder Cancer
Radiogenomics of Muscle Invasive Bladder Cancer
Enrollment Status: Terminated
Publish Date: April 18, 2024
Intervention Type: Diagnostic test
Study Phase: Not Applicable
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients With Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma Who Progressed on or After Platinum-Based Therapy
Enrollment Status: Completed
Publish Date: August 21, 2023
Intervention Type: Drug
Study Drugs: Ramucirumab, Docetaxel
Study Phase: Phase 3
Phase II Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer
Phase II Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2021
Intervention Type: Drug
Study Phase: Phase 2
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile
Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile
Enrollment Status: Terminated
Publish Date: November 08, 2019
Intervention Type: Biological, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

121 Total Publications

Diagnostic Accuracy of the Oncuria-Detect Multiplex Immunoassay in Detecting Upper Tract Urothelial Carcinoma.
Diagnostic Accuracy of the Oncuria-Detect Multiplex Immunoassay in Detecting Upper Tract Urothelial Carcinoma.
Journal: The Journal of urology
Published: October 03, 2025
Similar Doctors
Distinguished in Bladder Cancer
Dr. Charles O. Kim
Urology
Distinguished in Bladder Cancer
Dr. Charles O. Kim
Urology

Straub Benioff Medical Center - Pearlridge Clinic

98-151 Pali Momi Street, Suite 142, 
Aiea, HI 
 (7.5 miles away)
808-483-6400
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Charles Kim is an Urologist in Aiea, Hawaii. Dr. Kim is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Muscle Invasive Bladder Cancer, Ureteroscopy, and Vasectomy.

Advanced in Bladder Cancer
Dr. Manas Jain
Urology
Advanced in Bladder Cancer
Dr. Manas Jain
Urology

Straub Clinic And Hospital

888 S King St, 
Honolulu, HI 
 (0.1 miles away)
808-522-4000
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Manas Jain is an Urologist in Honolulu, Hawaii. Dr. Jain is rated as a Distinguished provider by MediFind in the treatment of Bladder Cancer. His top areas of expertise are Obstructive Uropathy, Hydronephrosis, Perirenal Abscess, Ureteroscopy, and Reconstructive Urology Surgery. Dr. Jain is currently accepting new patients.

Advanced in Bladder Cancer
Dr. Edith D. Canby
Urology
Advanced in Bladder Cancer
Dr. Edith D. Canby
Urology

Straub Medical Center Department Of Urology

888 S King St, 
Honolulu, HI 
 (0.1 miles away)
808-522-4301
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Edith Canby is an Urologist in Honolulu, Hawaii. Dr. Canby is rated as an Advanced provider by MediFind in the treatment of Bladder Cancer. Her top areas of expertise are Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Urothelial Cancer, Ureteroscopy, and Reconstructive Urology Surgery.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rosser's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile